The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation

Hyperprolactinemia (HP) is one of the most common neuroendocrine disorders. In 60% of cases, pathological HP is caused by pituitary prolactin-secreting adenoma. Therapy with agonists of dopamine type 2 receptors (D2 receptor agonists) is a method of choice for the treatment of pathological HP which...

Full description

Bibliographic Details

Published in:	Ожирение и метаболизм
Main Authors:	Zilya A. Kalmykova, Svetlana Y. Vorotnikova, Natalia S. Fedorova, Larisa K. Dzeranova, Ekaterina A. Pigarova, Aleksandr V. Vorontsov
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2019-09-01
Subjects:	hyperprolactinemia prolactinoma dopamine receptor agonists cabergoline resistance
Online Access:	https://www.omet-endojournals.ru/jour/article/view/10243